In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
0
0
0
Last 30D
0
1
0
0
0
1M Ago
0
0
0
0
0
2M Ago
1
2
0
0
0
3M Ago
0
0
0
0
0
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.75, a high estimate of $35.00, and a low estimate of $24.00. This current average reflects an increase of 10.19% from the previous average price target of $27.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Immunome is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Biren Amin
Piper Sandler
Announces
Overweight
$27.00
-
Brian Cheng
JP Morgan
Announces
Overweight
$24.00
-
Michael Schmidt
Guggenheim
Announces
Buy
$35.00
-
David Nierengarten
Wedbush
Raises
Outperform
$33.00
$27.00
Key Insights:
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Immunome. This offers insight ...Full story available on Benzinga.com
Benzinga
